Navigation Links
Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
Date:11/1/2010

high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese(TM)/Xerclear(TM). Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese(TM)/Xerclear(TM) is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear(TM) in Sweden and Finland.

For more information about Medivir, please visit the Company's website: http://www.medivir.se.

About TMC435 clinical trial programs

TMC435 is a once daily protease inhibitor jointly developed by Medivir and Tibotec Pharmaceuticals to treat hepatitis C virus infections. TMC435 is currently being studied in three phase 2b clinical trials (TMC435-C205, TMC435-C206 and TMC435-C215) in genotype 1 (G1) treatment-naive and in G1 patients that failed previous IFN-based treatment. TMC435 is planned to enter phase 3 studies early 2011.

PILLAR Study (TMC435-C205)

TMC435-C205 is an ongoing randomized double-blind global phase 2b study in 386 genotype-1 treatment-naive patients. It evaluates once daily treatment of TMC435 with different doses and durations given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A.

ASPIRE Study (TMC435-C206)

TMC435-C206 is an ongoing randomized double-blind global phase 2b study in 463 genotype-1 treatment-experienced patients. It evaluates once daily treatment of TMC435 in with different doses of given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A.

TMC435-C215

TMC435-C215 is a
'/>"/>

SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Medivir Interim Report, 1 January - 30 September 2010
2. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
3. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
4. Cord Blood America Continues to Reduce Debt; Three Notes Retired
5. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
6. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest
7. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
8. Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
9. Stryker Corporation Announces Pricing of Senior Notes
10. Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes
11. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Calif. , March 30, 2015  Cochlear ... has decided to leave Cochlear to join Valencia ... and friend, Jeff Greiner , who is ... Chief of Market Development and will be responsible ... of Valencia,s coin-sized neuromodulation ...
(Date:3/30/2015)...  Edison Nation Medical, the premier healthcare innovation ... innovations to assist seniors in staying mobile and ... 8-week search will be presented to major medical ... be submitted through a secure, confidential portal at ... The objective of the Senior Mobility ...
(Date:3/30/2015)... DURECT Corporation (Nasdaq: DRRX ) ... Phase 1 clinical trial of an oral formulation ... Regulator Program.  DUR-928 is an endogenous, small-molecule, new ... in metabolic diseases such as nonalcoholic fatty liver ... also play an important role in protecting against ...
Breaking Medicine Technology:Cochlear VP of U.S. Sales Jerry Schloffman Accepts Chief of Market Development Position at Valencia Technologies 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4
... LAKES, N.J., Jan. 4, 2011 BD (Becton, Dickinson and Company) ... announced today that it will present at the 29th Annual J. ... p.m. (ET). A live webcast of BD,s presentation ... and will be available for replay through Monday, January 17, ...
... (Nasdaq: ERES ), announced today that Dr. Joel ... Company,s Chief Financial Officer, are scheduled to present at the ... on January 13, 2011 in San Francisco, California. ... corporate website at http://www.ert.com . The webcast may also ...
Cached Medicine Technology:ERT to Present at the 29th Annual J.P. Morgan Healthcare Conference on January 13, 2011 2
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 Foundations ... proud to announce the start of its 41st national ... author Jane McGonigal, and former Congressman Patrick J. Kennedy ... Conference being held in San Diego, CA, March ... Coronado. The national conference brings together leading experts specializing ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 The Consumer Attorneys ... Skills for the New Attorney” seminar for attorneys who passed ... brings top trial attorneys in the Southern California area to ... Doctors on Liens was on hand, not ... to the doctors their clients will need to help in ...
(Date:3/30/2015)... March 30, 2015 KIND LED’s suite of ... light products in 2015. The excellent value and product features ... take the pole position in the race for the best ... the KIND LED suite of grow lights is the ... Photosynthetic Active Radiation (PAR) wavelengths that plants are most likely ...
(Date:3/30/2015)... Healtheminds, a start-up focusing on providing high ... easy to use and engaging online platform, is launching ... health related issues. The first in the series is ... other drugs. , Consumption and use of alcohol ... the toxic effects of excessive intake or drug overdoses, ...
(Date:3/30/2015)... 2015 Dr. Jeffrey Allred DDS, with his ... minute second opinion consultations for patients who need ... on dental second opinions show how small percentage of dentistry ... works. Only 6%” – says Dr. Allred. , “People ... fully trusting the dental care provider, for the simple fact ...
Breaking Medicine News(10 mins):Health News:Foundations Recovery Network Kicks Off Its 41st National Conference Specializing in the Treatment of Substance Abuse and Behavioral Health 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 3Health News:Best LED Grow Lights of 2015 Are Being Led By KIND LED 2Health News:HealthEminds Launching Webinar on Drug Dependence 2Health News:Allred Dental Offers Complimentary 15 Minute Consults with Dr. Jeffrey Allred in San Marcos, CA 2
... Cancer Center researchers have identified a new population of intestinal ... colorectal cancer. , This new stem cell population, reported March ... relatively quiescent (inactive) in contrast to the recent discovery ... marked by a protein, Lrig1, that may act as a ...
... Ill. -- The American Society for Gastrointestinal Endoscopy (ASGE) ... program specifically dedicated to promoting quality in endoscopy, in ... States. The ASGE Endoscopy Unit Recognition Program honors endoscopy ... assurance, endoscope reprocessing and CDC infection control guidelines. To ...
... News) -- Tourists over age 65 who visit malaria-infested regions are ... those ages 18 to 35, a new study says. The ... patients also found that the malaria death rate is particularly high ... of dying from malaria, an infection carried by mosquitoes, increased with ...
... with intensity modulated radiation therapy (IMRT) instead of standard ... acute or chronic toxicities, according to a study in ... official clinical practice journal of the American Society for ... determine the most effective breast cancer treatment that also ...
... 27 (HealthDay News) -- Women with ovarian cancer who ... have annual incomes of less than $35,000 are more ... Researchers found these racial and socioeconomic disparities in ... of surviving for five years after their cancer diagnosis. ...
... have identified genetic causes in nearly 1 in 5 patients ... Carolyn Jones, MD, PhD, of Loyola University Medical Center, ... of Cardiac Failure . First author is Neal Lakdawala, MD, ... on 264 patients with dilated cardiomyopathy and found that 17.4 ...
Cached Medicine News:Health News:Newly identified stem cells may hold clues to colon cancer 2Health News:ASGE recognizes 18 endoscopy units for quality 2Health News:Older Travelers at Much Higher Risk of Dying From Malaria 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Black Women, Uninsured Get Worse Ovarian Cancer Care: Study 2Health News:Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure 2
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
The 5524-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
The 9114-3.5 transducer is a versatile general imaging transducer. With multifrequencies, this transducer provides superb image quality and meets a multitude of imaging needs....
The versatility of multiple imaging frequencies and a smaller transducer face make this transducer is perfect for intercostal imaging....
Medicine Products: